Zheng Y, Shen H, Chen X, Feng J, Gao G
Arch Med Sci. 2024; 20(5):1619-1630.
PMID: 39649276
PMC: 11623155.
DOI: 10.5114/aoms/140293.
Galvez-Montosa F, Peduzzi G, Sanchez-Maldonado J, Ter Horst R, Cabrera-Serrano A, Gentiluomo M
Int J Cancer. 2024; 156(2):339-352.
PMID: 39319538
PMC: 11578083.
DOI: 10.1002/ijc.35196.
Chen Z, Xie C, Zeng W, Huang R, Yang J, Liu J
Signal Transduct Target Ther. 2024; 9(1):181.
PMID: 38992067
PMC: 11239683.
DOI: 10.1038/s41392-024-01896-z.
Wang Y, Vandewalle N, de Veirman K, Vanderkerken K, Menu E, de Bruyne E
Cell Commun Signal. 2024; 22(1):320.
PMID: 38862983
PMC: 11165851.
DOI: 10.1186/s12964-024-01699-3.
Kozalak G, Kosar A
Cancer Drug Resist. 2024; 6:838-857.
PMID: 38239705
PMC: 10792488.
DOI: 10.20517/cdr.2023.108.
Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma.
Rana P, Goparaju K, Driscoll J
Front Oncol. 2023; 13:1141851.
PMID: 37361580
PMC: 10285382.
DOI: 10.3389/fonc.2023.1141851.
Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.
Clavero E, Sanchez-Maldonado J, Macauda A, Ter Horst R, Sampaio-Marques B, Jurczyszyn A
Int J Mol Sci. 2023; 24(10).
PMID: 37239846
PMC: 10218542.
DOI: 10.3390/ijms24108500.
TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy.
Chen J, Cao W, Huang X, Chen Q, Ye S, Qu J
Blood Adv. 2023; 7(19):5752-5770.
PMID: 37083684
PMC: 10561007.
DOI: 10.1182/bloodadvances.2022008241.
Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma.
Bashiri H, Tabatabaeian H
Int J Mol Sci. 2023; 24(7).
PMID: 37046991
PMC: 10094562.
DOI: 10.3390/ijms24076019.
Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies.
Kozalak G, Butun I, Toyran E, Kosar A
Pharmaceuticals (Basel). 2023; 16(1).
PMID: 36678608
PMC: 9864669.
DOI: 10.3390/ph16010111.
Autophagy in Hematological Malignancies.
Garcia Ruiz O, Sanchez-Maldonado J, Lopez-Nevot M, Garcia P, Macauda A, Hernandez-Mohedo F
Cancers (Basel). 2022; 14(20).
PMID: 36291856
PMC: 9600546.
DOI: 10.3390/cancers14205072.
Targeting the β -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.
Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R
J Pathol. 2022; 259(1):69-80.
PMID: 36245401
PMC: 10953387.
DOI: 10.1002/path.6020.
Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma.
Johnstone M, Vinaixa D, Turi M, Morelli E, Anderson K, Gulla A
Cells. 2022; 11(16).
PMID: 36010596
PMC: 9406519.
DOI: 10.3390/cells11162519.
The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas".
Solimando A, Da Via M, Bolli N, Steinbrunn T
Cancers (Basel). 2022; 14(13).
PMID: 35805041
PMC: 9265748.
DOI: 10.3390/cancers14133271.
Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma.
Li L, Chen T, Wang J, Li M, Li Q
J Immunol Res. 2022; 2022:3922739.
PMID: 35677537
PMC: 9169202.
DOI: 10.1155/2022/3922739.
Dusquetide modulates innate immune response through binding to p62.
Zhang Y, Towers C, Singh U, Liu J, Hakansson M, Logan D
Structure. 2022; 30(8):1055-1061.e7.
PMID: 35640615
PMC: 9357125.
DOI: 10.1016/j.str.2022.05.003.
Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma.
Han Q, Bai H, Xu Y, Zhou M, Zhou H, Dong X
Clin Exp Pharmacol Physiol. 2022; 49(6):674-685.
PMID: 35294057
PMC: 9310729.
DOI: 10.1111/1440-1681.13643.
PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population.
Wang Y, Yao L, Teng Y, Yin H, Wu Q
Front Oncol. 2022; 11:783583.
PMID: 35083142
PMC: 8784391.
DOI: 10.3389/fonc.2021.783583.
Endoplasmic Reticulum Quality Control in Immune Cells.
Jiang Y, Tao Z, Chen H, Xia S
Front Cell Dev Biol. 2021; 9:740653.
PMID: 34660599
PMC: 8511527.
DOI: 10.3389/fcell.2021.740653.
Research progress in proteasome inhibitor resistance to multiple myeloma.
Wu J, Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46(8):900-908.
PMID: 34565737
PMC: 10929973.
DOI: 10.11817/j.issn.1672-7347.2021.200430.